The expanding actions and improved efficacy of modern GLP-1 receptor agonists (GLP-1RAs) have led to increasing utilization of these medicines for people with T2D and obesity [[2], [3], [4], [5], [6]]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.